Context Therapeutics (NASDAQ:CNTX) Inc CEO Martin Lehr tells Proactive it closed 2021 with a balance sheet of nearly $50 million. As of December 31, 2021, the women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers said its cash, cash equivalents, and restricted cash were $49.7 million -- compared to $0.3 million at the end of 2020.
In March 2022, the company noted it announced the acceptance of five abstracts that highlight new preclinical data on ONA-XR and Claudin 6 programs that will be presented at the American Association for Cancer Research Annual Meeting 2022 on April 8-13 in New Orleans.
It will host a webinar to discuss programs on April 13. Viewers interested in joining the webinar can do so here: https://edisongroup.zoom.us/webinar/register/WN_AczVH-d_QMy5qcT_enL3ww